HairDX Launches European Subsidiary To Expand Global Availability Of Genetic Baldness Test For Men And Women

International report - Pharmacogenomics research and development innovator PharmaGenoma, Inc. and its subsidiary HairDX, LLC(www.hairdx.com), pioneers of genetic tests for predicting the risk of male and female hair loss, today announced the launch of its European subsidiary,HairDX Europe.

HairDX Europe expands the company’s leadership in hair dermatology, and global availability of the genetic tests for Androgenetic Alopecia. This follows the recent announcement of distribution agreements with Biodue inItaly, and Aderans in Japan. HairDX's revolutionary genetic tests in Italy, and further expands the company's leadership in the dermatology of hair.

Dirk Segers will serve as President of HairDX Europe. He has worked and managed European subsidiaries for U.S. based medical device start-up companies, and brings 18 years of experience in clinical, sales andmarketing management. Segers also founded a consulting company called Euramedics bvba and has worked previously at ValleyLab, Colorado, a subsidiary of Pfizer Inc. He holds a master of science in nuclear physics, a master in quantitative business and a master of business administration.

"The launch of HairDX Europe solidifies PharmaGenoma’s position as a globalpioneer in genetic testing and molecular dermatology," Mr. Segers says. "Having a Belgian office will enable HairDX to expand its reach throughout the continent."

HairDX's easy to use genetic test provides an accurate and understandable genetic analysis of a man's or woman's likelihood of developing Androgenetic Alopecia, the most common type of hair loss.

"We are very excited to introduce the HairDX's genetic test throughout Europe," says Andy Goren, president & CEO of PharmaGenoma, Inc. "As the firstgenetic test for baldness, it will be of great help to Dermatologists offer earlier hair loss treatment to their patients."